Ask the Experts
Meet our Expert: Iain Shaw
Iain Shaw: Senior Director, 14C Enabled Drug Development
Iain Shaw is Senior Director of 14C Enabled Drug Development at Quotient Sciences. Iain has over 30 years of experience in the pharmaceutical industry, including more than 20 years of drug development experience. Iain initially joined Pharmaceutical Profiles, which later became Quotient Sciences, as Director of Customer Service in 2008.
Prior to joining Quotient Sciences, Iain held early development program management, clinical development, and analytical positions at pharmaceutical companies and contract research organizations (CROs) including Covance (now Lab Corp Drug Development) and PPL Therapeutics.
Iain holds a Bachelor of Science in Agricultural Chemistry from the University of Glasgow.
Topics of interest
Connect on LinkedIn
Ask a question
Have a question for Iain Shaw about human ADME studies? Please submit your question along with your contact information below.
Webinar
Streamlining the Delivery of 14C Human ADME Data: An ADME Q&A Roundtable
Hear Iain Shaw, Senior Director of 14C Enabled Drug Development at Quotient Sciences, and Wouter Vaes, microtracer expert at The Netherlands Organization for Applied Scientific Research (TNO), discuss techniques for streamlining human ADME studies in our on-demand webinar. You'll learn about:
- Challenges and considerations when conducting a human ADME study
- Regulatory requirements for human ADME studies
- Utilizing a U-tracer study versus a classical human ADME study approach
- Advantages in conducting microtracer accelerator mass spectrometry (AMS) studies in early clinical development
- Benefits of an integrated Synthesis-to-Clinic® approach in delivering ADME studies